Oral thin films
An orally soluble film with ion exchange resin technology addresses swallowing difficulties by providing immediate and sustained drug release, ensuring accurate dosing and safety for patients with dysphagia or pediatric patients.
Patent Information
- Application Number
- JP2024113813
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-07
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing oral dosage forms of morphine, such as tablets and liquid solutions, are difficult for patients with dysphagia or pediatric patients to swallow, leading to inaccurate dosing and potential toxicity from excipients, and there is a need for innovative formulations that provide controlled and sustained drug release.
Development of an orally soluble film comprising a pharmaceutically active ingredient and a resinate containing an ion exchange resin, which allows for immediate and sustained release of drugs, suitable for patients with swallowing difficulties, using a matrix and/or binder with polymers that dissolve in the oral cavity.
The film provides accurate and convenient drug delivery with immediate and sustained release profiles, reducing the need for water and minimizing exposure to harmful excipients, suitable for pediatric and geriatric patients.
Smart Images

Figure 2024156712000001_ABST
Abstract
Description
[Technical field]
[0001] Drug delivery systems, and in particular drug delivery systems in the form of oral thin films . [Background technology]
[0002] Many medical and / or pathological conditions are caused by the administration of chemical and / or pharmaceutical agents to a subject. An example of a common application requiring drug delivery is pain relief. It is a treatment for pain.
[0003] Morphine is the "gold standard" treatment for severe pain. It is generally accepted that there is a Administration of tinea gracilis is currently considered the first-line treatment for severe pain in adults with advanced cancer. (Scottish Intercollegiate Guidelines Network, Control of pain in adults with c answer. SIGN Guideline No. 106., SIGN, Edinburgh, 2008), and As a first-line treatment for children with persistent moderate to severe pain (World Health Organisation zation, WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Ch. aged persons with medical illnesses, World Health Organization, Geneva, 2012), It is coming.
[0004] The use of morphine as an analgesic in moderate to severe pain is similar to that of morphine. Nexon reported that approximately half of general cancer patients experience shortness of breath as a symptom. It is also commonly used to treat shortness of breath as part of palliative care (DJ Dudgeon , L. Kristjanson, JA Sloan, M. Lertzman, K. Clement, Dyspnea in cancer patients s; prevalence and associated factors, J Pain Symptom Manag, 21 (2001) 95-102). Also, the use of low-dose opioids (e.g., morphine, naphthalene, naphthalene, Regarding the off-label use of drugs such as hine, as part of palliative care, national guidelines This is recommended in the SIGN Guideline on Management of Chronic Heart Failure (SIGN Guideline N o. 95., SIGN, Edinburgh, 2007). Ne is also recommended in chronic heart failure (DC Currow, C. McDonald, S. Oaten, B. Kenny, P. Allcroft, P. Frith, M. Briffa, MJ Johnson, AP Abernethy, Once-dail y opioids for chronic dyspnea: a dose increment and pharmacovigilance study, Jou Journal of Pain and Symptom Management, 42 (2011) 388-399). The drug can maintain a constant blood concentration and therefore avoid withdrawal symptoms. It has also been shown to be beneficial in discontinuing high doses of morphine because it can (A. Ahmed, H. Khurana, V. Gogia, S. Mishra, S. Bhatnagar, Use of sustain ed release oral morphine as a bridge in withdrawal of morphine in patients on hi gh doses of oral immediate release morphine for cancer pain, The American journa Journal of Hospice & Palliative Care, 27 (2010) 413-415. Many sustained release oral The convenience of taking hine products twice daily promotes patient compliance Meanwhile, blood levels are sustained, improving pain management and symptom control. (CM Amabile, BJ Bowman, Overview of oral modified-release opioid p roducts for the management of chronic pain, The Annals of pharmacotherapy, 40 (2 006) 1327-1335).
[0005] However, the available approved oral dosage forms of morphine have their limitations. Tablets (Sevredol (登録商標) , Morphgesic (登録商標) , MST (登録商標) Continues (登録商 標) ) or capsules (Zomorph (登録商標) , MXL (登録商標) ) solid forms are difficult to swallow Dysphagia can be a problem for patients with This is a common problem and an important aspect of end-of-life care. are often more difficult to swallow; the European Medicines Agency recommends that tablets / capsules be used in children under 2 years of age. The Committee for Medicinal Products for Children does not believe that it is available or applicable for use in children. ts for human use (CHMP), Reflection paper: formulations of choice for the paedia Children aged 2 to 6 years were given various doses depending on their development and tablet size. (A. Zajicek, MJ Fossler, JS Barrett, JH Worthington, R. Tern ik, G. Charkoftaki, S. Lum, J. Breitkreutz, M. Baltezor, P. Macheras, M. Khan, S. Agharkar, DD MacLaren, A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms, AAPS J, 15 (2013) 1072-1081). Oral solution (Oramorph (登録商標) ) is useful for some patients with swallowing disorders, but In pediatrics, there are no approved drug formulations for different ages. and off-label use of adult medicines in children is widespread. The need to constantly measure small volumes or to dilute or reconstitute commercial products can The need to complete a single dose can lead to inaccurate dosing in this population. Many liquid drug formulations, such as Oramorph (登録商標) is not recommended in pediatric patients. It must contain excipients such as alcohol or preservatives that may have harmful or toxic effects (V Fabiano, C. Mameli, GV Zuccotti, Paediatric pharmacology: remember the excip ients, Pharmacol Res, 63 (2011) 362-365). MST (登録商標) Continues (登録商標) (Napp Pharmaceuticals Ltd.; Cambridge, a subsidiary of Pharmacy, has developed a suspension for the controlled release administration of morphine. It is available as a granule that is reconstituted as a cloudy solution. The twice-daily preparation is attractive, but This formulation again requires further manipulation before administration. The granules are dispersed in at least 10 to 30 mL of water (Napp Pharmaceuticals Limited). ted, MST Continus suspensions 20, 30, 60, 100 and 200 mg - Summary of Product Ch aracteristics (SPC), in: electronic Medicines Compendium (eMC), 2014). For smaller doses (e.g., smaller pediatric doses), smaller aliquots may be required. This not only depends on accurately measuring small volumes, Dosing inaccuracies may occur due to settling of granules or uneven suspension. For these reasons, innovative formulation strategies to deliver morphine more effectively are needed. It continues to be needed.
[0006] Optimizing the blood concentration-time profile of some drugs with short half-lives, such as morphine To facilitate the delivery of effective and / or less frequent dosing, formulators must consider the dosage form distribution in the gastrointestinal tract. Many researchers have sought to develop new techniques to delay or extend the drug release from Examples include entrapment of the drug in a slowly dissolving matrix, coating of the tablet, Addition of a coating to provide pH-dependent solubility and to control drug release and osmotic pressure control systems using semipermeable membranes (MJ Rathbone, J. Hadgraft, MS Roberts, Recent advances and future directions in modified-release delivery system stems for oral administration, in: Modified-Release Drug Delivery Technology, T Aylor & Francis, 2002).
[0007] A known method of orally administering a substance to a patient is the oral thin film. The term "Oral Thin Film" is used in the art. It is a term known in the art, and the term "thin" should be understood as a relative term. The recognized phrase "oral synovial drug" refers to a type of product that is not prescribed by the art and is widely understood by those skilled in the art. It is understood simply as having a recognizable meaning as part of the "film." Other synonymous terms to describe the type of product are "Oral Dissolving Films" e Films”, “Thin Dissolving Films”, “Oral Dispersible Films” "Orodispersible Films", "Oral Consumable Films", "Oral "Oral Drug Strips" or "Oral Films."
[0008] OTFs are capable of dissolving rapidly in the oral cavity of a subject and are primarily composed of water-soluble film-forming polymers. OTFs were originally developed as breath fresheners and contain active pharmaceutical ingredients (APIs). The technology has progressed to deliver pharmaceutical ingredients (APIs) orally. However, when placed in the subject's mouth, they do not require chewing or drinking water. These films dissolve rapidly in saliva without any food or pharmaceutical grade contamination. They are formulated using standard excipients and are inexpensive to manufacture. As a holistic platform, these films can be formulated without the need for preservatives or solvents. i.e., administering a liquid formulation can eliminate potentially harmful excipients. This makes it an attractive option for drug delivery in children, where exposure to do.
[0009] Typically, oral thin films can achieve drug loadings of 5-30%. And by adjusting the dimensions of the film, the target drug content can be easily controlled. (RP Dixit, SP Puthli, Oral strip technology: overview and future potential, J Control Release, 139 (2009) 94-107). In general, oral thin-film The target surface area must be between 5 and 20 cm to allow for practical dose administration. 2 (A.A rya, A. Chandra, V. Sharma, K. Pathak, Fast dissolving oral films: an innovative drug delivery system and dosage form, Int J ChemTech Res, 2 (2010) 576-583). Ma In addition, the thickness of the film can be easily controlled. Many different film-forming polymers are available that have film adhesion properties. Including taste-masking techniques, as well as sweeteners and flavoring agents to provide acceptable, palatable drug delivery. The system can be generated.
[0010] Ion exchange resins (IER) are resins that carry positively or negatively charged sites (exchange reactions) (capable of capturing ions of the opposite charge in water) Through this process, the ion exchange resin is "loaded" with the drug molecule. " to form a drug-resin complex known as a resinate (RN Shamm a, EB Basalious, RA Shoukri, Development and optimization of a multiple-unit controlled release formulation of a freely water soluble drug for once-daily ad ministration, International journal of pharmaceutics, 405 (2011) 102-112). Ion exchange resins are available in a variety of particle sizes and have good mechanical strength and physicochemical stability. Indicates qualitative.
[0011] PCT Publication No. WO 01 / 70194 (BESS et al.) discloses a method for the preparation of pharma- ceutical active agents and methods for the preparation of pharma-ceutical active agents. The present invention discloses an orally consumable film comprising an ion exchange resin used as a taste masking agent for is doing.
[0012] PCT Publication No. WO 2013 / 171146 (LI) describes a method for the preparation of a medicament for the treatment of osteoarthritis by including an opioid agonist in a resinate. The present invention discloses an oral film having a controlled release layer comprising a sedative agent, the film comprising: Separate mucosa containing opioid antagonists to avoid extraction into the method It has an adhesive layer.
[0013] PCT Publication No. WO 2009 / 099830 (BUNICK et al.) discloses a method for producing a medicament comprising two or more segmented portions. The present invention discloses an edible film that contains an active ingredient distributed over segmented portions. is doing. Summary of the Invention [Problem to be solved by the invention]
[0014] The object of the present invention is to avoid or at least one of the above-mentioned problems associated with the prior art. The aim is to reduce it. [Means for solving the problem]
[0015] According to a first aspect, there is provided an orally dissolvable film comprising at least one layer comprising: Can be: a first pharma- ceutical active ingredient; a resinate comprising an ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
[0016] The first pharma- ceutical active ingredient and the second pharma- ceutical active ingredient may be the same, or may vary.
[0017] The first pharma- ceutical active ingredient is provided on (e.g., on) the film; or applied (e.g. imprinted, coated, spread The first pharma- ceutical active ingredient may be provided or incorporated within the film. It may be absorbed, dispersed, or dissolved in water. The first pharma- ceutical active ingredient may be provided or incorporated homogeneously within the film. may be homogeneously absorbed, dispersed, or dissolved.
[0018] The resinate is dispersed in the film (e.g., in the at least one layer). The particles may be dispersed uniformly (eg, unevenly dispersed).
[0019] The first pharma- ceutical active ingredient is incorporated into the film (e.g., into the at least one layer). ), in an amount of about 0.1 to 50% by weight (e.g., about 1 to 20% by weight, typically about 2 to 10% by weight). This may happen.
[0020] The resinate is incorporated into the film (e.g., into the at least one layer) in an amount of about 1 to 20% by weight. It may be provided in an amount of 50% by weight (eg, typically about 5-20% by weight).
[0021] The ratio (weight ratio) of the second pharma- ceutical active ingredient to the resin in the resinate is about 2:1 to 1:5, typically Typically, the ratio may be about 1:1 to 1:2 (eg, about 1:1.5).
[0022] The film (e.g., at least one layer) may include a matrix and / or binder. Preferably, the film comprises a polymer matrix. The matrix is a material that is compatible with the remaining components of the film (e.g., at least It is capable of acting as a binder for the 1st pharma- ceutical active ingredient and the resinate. There is a saying.
[0023] Advantageously, the matrix comprises a dissolvable polymer matrix. There is a saying.
[0024] Preferably, the matrix dissolves, disintegrates, and / or degrades in the subject's oral cavity. There are times when this happens.
[0025] Typically, the matrix polymer is a cellulosic polymer and / or a derivative thereof. Materials (e.g., one or more of synthetic or natural rubbers, cellulose derivatives [cellulose, ethyl Cellulose, Hydroxyethyl Cellulose, Hydroxypropyl Methyl Cellulose , Carboxymethyl Cellulose, Sodium Carboxymethyl Cellulose, Carbo Sodium hydroxymethylcellulose, Hydroxypropyl methylcellulose, Hydroxy propyl cellulose, etc.], polysaccharides [pullulan, carrageenan, alginic acid and / or its salts, pectin, xanthan gum and / or its derivatives, starch and / or its derivatives, etc. It may also include (e.g.)
[0026] The matrix polymer may be a synthetic polymer (e.g., acrylic acid (co)polymer and / or or its derivatives, polyalkylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, carboxyvinyl polymers, and / or their derivatives) There is.
[0027] Those skilled in the art will appreciate that the matrix may comprise one or more polymers or a combination of polymers. These are used to produce films with desired properties (e.g., strength and / or flexibility, etc.). The desired mechanical properties of the composition, as well as the desired dissolution rate in the oral cavity of the subject, are selected to achieve the desired You will understand that there is a choice to be made.
[0028] A first pharmaceutical agent dispersed or dissolved in the film (e.g., in the at least one layer). and a resinate comprising an ion exchange resin and a second pharma- ceutical active ingredient. and providing an immediate release of the first active ingredient and a controlled, sustained release of the second active ingredient. This allows for immediate delivery of a predetermined amount of the first active ingredient, and / or delayed release. and sustained release of the second active ingredient over a period of time. Such formulations may be particularly advantageous for use in combination with other solid oral dosage forms, e.g. Ideal for patients (e.g., children or elderly patients) who have difficulty swallowing tablets. may be suitable for certain purposes.
[0029] Those skilled in the art will appreciate that the term "immediate release" refers to the fact that the film, e.g. When dissolved in the oral cavity of a subject, the first pharma- ceutical active ingredient is delivered without delay. Therefore, the term "immediate" is understood in an absolute sense. For example, the film may be dissolved in the oral cavity of the subject, This takes into account the time required to release one pharma- ceutical active ingredient.
[0030] Typically, the film (e.g., the at least one layer) is heated for less than 1 minute, e.g., 45 It may dissolve in the patient's mouth in less than a second, preferably less than 30 seconds.
[0031] The first pharma- ceutical active ingredient and the second pharma- ceutical active ingredient may be the same. In such cases, the orally dissolvable film may include at least one layer comprising: R: a first amount of a pharma- ceutical active ingredient provided in at least one layer; a resinate comprising an ion exchange resin and a second amount of a pharma- ceutical active ingredient; and Matrix and / or binder.
[0032] In the film (e.g., in the at least one layer), a first amount of a pharma- ceutical active ingredient (dispersed or dissolved), and an ion exchange resin and a second amount a resinate containing a pharma- ceutical active ingredient, whereby the active ingredient (e.g., a first amount of the active ingredient) and controlled and / or delayed release of the active ingredient (e.g., a second amount of the active ingredient). This allows for immediate delivery of a given amount of the active ingredient, and extended release of the active ingredient. This is particularly advantageous when a patient requires sustained release over a period of time. This is especially true, for example, in thin films formulated for the treatment of pain. This can be beneficial because such formulations can provide a predetermined amount of pain relief to a subject. allowing immediate delivery of a pain relieving agent (e.g., morphine) to relieve pain, and and administering a delayed and / or sustained release of an analgesic agent (e.g., morphine) to the subject at a certain time point. Such a formulation allows for the delivery of a resinate that provides a long-term Patients who have difficulty swallowing other solid oral dosage forms (e.g., tablets, etc.) (e.g., pediatric may be ideally suited for some patients (young children or elderly patients).
[0033] In the film (e.g., in the at least one layer), multiple (e.g., two or more) For example, the film may contain a pharma- ceutical active ingredient (e.g., In some cases, multiple (e.g., two or more) pharma- ceutical active ingredients may be dispersed in one layer. .
[0034] Multiple (e.g., two or more) resinates may be provided. For example, the film (e.g., For example, the at least one layer comprises a first ion exchange resin and a first pharma- ceutical active ingredient. a first resinate containing a second ion exchange resin and a second pharma- ceutical active ingredient; wherein the first and second pharmacoactive ingredients are different. Further pharma- ceutical active ingredients, each of which comprises an ion exchange resin and a respective pharma- ceutical active ingredient, Resinates that are suitable for use in dental implants may also be provided.
[0035] The term resinate is used herein to refer to a compound that is bound to an ion exchange resin or that is an ion-exchange resin. means a combination of a pharma- ceutical active ingredient complexed with an exchange resin; I understand.
[0036] Ion exchange resins are made up of positively or negatively charged sites (those with opposite charges in the exchange reaction). It is a water-insoluble polymeric compound that contains either Ion exchange resins are typically used as cation exchange resins or as anion exchange resins. Cation exchange resins are ion exchange resins that have negatively charged moieties, e.g. For example, in a liquid, a cationic pharmacoactive ingredient can be bound. The drug can then be Once equilibrium is reached at high electrolyte concentrations, the bound cations and the interacting pharmacologically active The active ingredient may, for example, be released in vivo.
[0037] In one embodiment, the ion exchange resin is a sulfonic acid modified styrene-divinylbenzene copolymer. The ion exchange resin may contain a strong acid cation resin, such as a polymeric resin. In some cases, substances may be selected to be considered safe additives in the manufacture of food and beverages. For example, The resin is compliant with Title 21, Part 17 of the Code of Federal Regulation (CFR). 3(https: / / www.gpo.gov / fdsys / pkg / CFR-2010-title21-vol3 / pdf / CFR-2010-title21-vol3- The resin may be one or more of the following: You have to choose from above: - sulfonated copolymers of styrene and divinylbenzene; - ASTM Test Method D388-38, Class I, Group 2, ''Standard Specifications for Cla ssification of Coal by Rank,' (http: / / www.archives.gov / federal_register / code_of _federal_regulations / ibr_locations.html), which is incorporated by reference. Sulfonated anthracite coal meets the above requirements; - Sulfite-modified crosslinked phenol-formamide with side chain sulfonate modification aldehyde; - methacrylic acid-divinylbenzene copolymer; - Crosslinked polystyrene (first chloromethylated, then trimethylamine, dimethyl aminated with amine, di-ethylenetriamine, or dimethylethanolamine); - Diethylenetriamine, triethylenetetramine, or tetraethylenepentamine (crosslinked with epichlorohydrin); - Triethylene, tetramine, and / or tetraethylenepentamine Activated cross-linked phenol-formaldehyde; - reaction resin of formaldehyde, acetone and tetraethylenepentamine; - fully hydrolyzed copolymer of methyl acrylate and divinylbenzene; - Complete hydrolysis of methyl acrylate, divinylbenzene, and acrylonitrile copolymer; - Sulfur compounds of styrene, divinylbenzene and acrylonitrile or methyl acrylate ternary copolymer; - Methyl acrylate-divinylbenzene copolymer containing 2% by weight or more of divinylbenzene Copolymer (aminolyzed with dimethylaminopropylamine); - Methyl acrylate-divinylbenzene copolymer containing 3.5% by weight or more of divinylbenzene Copolymer (aminolyzed with dimethylaminopropylamine); - epichlorohydrin bridged with ammonia; - For mixtures of monomers containing not more than 2% by weight in total of acrylonitrile and methyl acrylate The sulfur compounds derived from styrene, divinylbenzene, acrylonitrile and methyl acrylate HONDA TETRAPOLYMER; - Divinylbenzene 3.5% by weight or more, and diethylene glycol divinyl ether Methyl acrylate-divinylbenzene-diethylene glycol containing 0.6% by weight or less of terephthalate Divinyl ether terpolymer (aminolysis with dimethylaminopropylamine) olyzed); - Styrene-divinylbenzene crosslinked copolymer (first chloromethylated, then dimethylated) The resin was aminated with vinyl N,N-dimethylamine and oxidized with hydrogen peroxide. containing not more than 15% by weight of benzylamine-N-oxide and not more than 6.5% by weight of nitrogen; - Divinylbenzene 7% by weight or more, and diethylene glycol divinyl ether Methyl acrylate-divinylbenzene-diethylene glycol containing 2.3% by weight or less Terpolymer of phenyl divinyl ether (aminolysis with dimethylaminopropylamine ( aminolyzed), and quaternized with methyl chloride); - Crosslinked with ammonia, then quaternized with methyl chloride, and the total exchange capacity was calculated by weight. epichlorohydrin, which contains not more than 18% of a strong base; - Crosslinking and alkylation using epichlorohydrin and propylene oxide Then, it is sulfonated, which results in the synthesis of epichlorohydrin and propylene oxide. Regenerated cellulose in an amount not to exceed 250% by weight of the starting amount of cellulose.
[0038] The specific choice of resin to use for a particular application may be required for a particular active ingredient or drug. The required release rate, the environment in which the active ingredient or drug is to be released (e.g., intestinal release, stomach release, release at room temperature, etc.) and the chemical properties (e.g. charge) of the active ingredient or drug. For example, the ion exchange resin and the active ingredient may be mutually charged. The ion exchange resin may be charged in such a way that its charge is opposite to that of the active ingredient. If a negatively charged active ingredient is to be used, the above-mentioned Ion exchange resins can be positively charged resins. Use a positively charged active ingredient. In the case of a neutrally charged ion exchange resin, the ion exchange resin may be a negatively charged resin. If it is intended to use a modified or neutral active ingredient, the ion exchange resin is more weakly By mixing small charges (e.g. dipoles) or by complexing with the counter ions of the resin The polymer may bond to or form a complex with the resin via
[0039] The first pharma- ceutical active dispersed in the film is associated with a first release rate. There are times when this happens.
[0040] The first release rate may be at least 30%, e.g., at least 20%, after 5 minutes when measured at pH 6.8. It may be at least 50%.
[0041] The first release rate may be at least 40%, e.g., at least 20%, after 10 minutes when measured at pH 6.8. It may be at least 60%.
[0042] The first release rate may be at least 50%, e.g., at least 50%, after 5 minutes when measured at pH 1.2. It may be at least 60%.
[0043] The first release rate may be at least 60%, e.g., at least 20%, or at least 60% after 10 minutes when measured at pH 1.2. It may be at least 80%.
[0044] The second pharma- ceutical active ingredient contained in the resinate is associated with a second release rate. There are times when this happens.
[0045] The second release rate may be about 5 to 80%, for example about 10 to 80%, after 1 hour when measured at pH 6.8. It can be as high as 60%.
[0046] The second release rate is about 10 to 80%, for example about 20%, after 2 hours when measured at pH 6.8. It can be up to 70%.
[0047] The second release rate is about 10 to 80%, for example about 20%, after 1 hour when measured at pH 1.2. It can be up to 60%.
[0048] The second release rate is about 20 to 90%, for example about 30%, after 2 hours when measured at pH 1.2. It can be up to 80%.
[0049] The ion exchange resin may typically be provided in the form of beads.
[0050] The beads may be of a relevant particle size, e.g., average size, or a relevant mesh size. It may have noise.
[0051] The mesh size and / or particle size of said ion exchange resin or mixture of ion exchange resins The size of the formulation can be selected to provide a desired release rate for the active ingredient or drug. be.
[0052] Without wishing to be bound by theory, the mesh size and and / or particle size may affect the release rate of a given drug under certain conditions. In particular, the smaller the mesh size (i.e., the larger the particle size), the larger the amount of granular matter. The drug resinates prepared using the resins shown in Fig. 1 have a relatively high mesh size (i.e., The release rate is faster than that of drug resinates prepared using resins with relatively low particle size. It has been observed that the intensity may be reduced.
[0053] The resin may have a mesh size ranging from 50 to 100 mesh size. and / or particle sizes in the range of 150 to 300 μm. Resinates prepared using this method have been associated with a relatively low release rate of the drug or active ingredient. There is a saying.
[0054] The resin may have a mesh size ranging from 100 to 200 mesh size. and / or particle sizes in the range of 74 to 150 μm. Resinates prepared using this method are associated with moderate release rates of the drug or active ingredient. There is.
[0055] The resin may have a mesh size ranging from 200 to 400 mesh size. and / or particle sizes in the range of 37 to 74 μm. Resinates prepared in this manner are associated with relatively high release rates of the drug or active ingredient. There is.
[0056] The second release rate was measured at pH 1.2 for a resin having a mesh size of about 50-100. When measured, after 1 hour, it may be about 10 to 70%, for example, about 20 to 60%.
[0057] The second release rate was measured at pH 1.2 for a resin having a mesh size of about 200 to 400. When measured at 100° C., after 2 hours the concentration may be about 30 to 99%, for example about 50 to 95%.
[0058] The ion exchange resin and / or resinate may be provided in the form of particles (e.g., beads). This may also be the case.
[0059] The resinate (e.g., beads) may be processed (e.g., coated, encapsulated, etc. By applying a coating to the resinate particles, The initial release of the second active ingredient from the resinate may be altered (e.g., delayed). This is because the second active ingredient is released in a specific area of the subject's anatomy (e.g., For example, it may bypass release in one or more areas of the digestive system [e.g., the stomach] and enter one or more areas of the digestive system. In some cases, release in other areas of the body (e.g., the small intestine) may be particularly beneficial. The sealing material (e.g., coating) is applied to one or more regions of the digestive system (e.g., the stomach) to inhibit digestion. Resists dissolution or dissolution and disintegrates in one or more other areas of the digestive system (e.g., the small intestine). For example, the ion exchange resin may be selected to dissolve the ion. When the desired release rate and / or release profile cannot be obtained by using the resin alone, Coating the resinate particles also inhibits the release of the second active ingredient from the resinate. Sometimes it is useful to fine-tune the exit velocity.
[0060] In some embodiments, the orally dissolvable film may further comprise an optional additive, such as, for example, one or more disintegrants, surfactants [e.g., emulsifiers], plasticizers, fillers, flavoring agents, sweetening agents, Colorants, antioxidants, microbial preservatives, etc.
[0061] The film (e.g., the at least one layer) may be free or unloaded. In some embodiments of the present invention, the ion exchange resin may be further loaded. An orally dissolvable film is provided, comprising at least one layer comprising: a first pharma- ceutical active ingredient dispersed in at least one layer; a resinate comprising a first ion exchange resin and a second pharma- ceutical active ingredient; a second ion exchange resin; and Matrix and / or binder.
[0062] The first ion exchange resin and the second ion exchange resin can be the same; may vary.
[0063] The second ion exchange resin is distributed in the film (e.g., in at least one layer). The second ion exchange resin is not complexed with a pharma- ceutical active ingredient. It may not require any special software and is sometimes referred to as unloaded or free.
[0064] Advantageously, by incorporating free ion exchange resin in the film, This can alter the release profile of the first and / or second pharma- ceutical active ingredients. Without wishing to be bound by theory, it is believed that free ion exchange resins are The first pharma- ceutical active ingredient is dispersed in the foam (e.g., in at least one layer). and / or a second pharma- ceutical active component that may be released from said resinate. It is believed that the first and / or second pharmacologically active ingredient may interact with the The release profile and / or rate of the active ingredient is determined by administering a first amount of a first infusion solution to the resinate. a second amount of the second ion exchange resin as unloaded or free resin; The first resin and the second resin can be adjusted by selecting the ion exchange resin. The second resin may be the same or different. Advantageously, in the film By adding "free" ion exchange resin to the The first and / or second resins are more readily absorbent than the same film without the resin over a period of time. This may result in a more consistent release profile for the active ingredient.
[0065] the first pharma- ceutical active ingredient and / or the second pharma- ceutical active ingredient comprises a therapeutic agent; or In other words, the term "pharmaceutical active ingredient" may be a therapeutic drug. The term "active ingredient" as used herein refers to a compound that can have a therapeutic effect on a patient ( "active ingredient" refers to an active ingredient that is capable of treating a disease and / or medical condition. And there is something to understand.
[0066] In one embodiment, the first pharma- ceutical active ingredient and / or the second pharma- ceutical active ingredient are a drug or substance capable of reducing pain in a subject (e.g., an analgesic); may consist of.
[0067] The first and / or second pharmacokinetically active ingredient (e.g., pharmacokinetically active ingredient) may be an opioid drug. The first and / or second The pharmacoactive ingredient (e.g., the pharmacoactive ingredient) may be any other drug class, including, but not limited to, The first and / or second pharma- ceutical active ingredients (e.g., Ingredients) include one or more of alfentanil, allylprozin, alphaprozin, and amphotericin. Epramon, amphetamine, amphetamine, anileridine, apocomil Apocodeine, apomorphine, asimadoline, axomadol, benzylmorph benzylmorphine, bezitramide, bremazocine, briffentanil brifentanil), buprenorphine, butorphanol, carfentanil, clonitazene , codeine, cyclazocine, cyclorphan, cyprenorphine, cyproda Cyprodime, deltorphin, desomorphine, dextromethorpha Dextromoramide, dextropropoxyphene, dezocine, diamorphine, dimorphine Amorphone, diampromide, diacetylmorphine, dihydrocodeine , dihydrocodeinone, dihydroetorphine, dihydromorphine , dimenoxadol, dimephetamol, dimephetanol, dimethyl Thiambutene, dioxyaphetyl butyrate, diphenox Silane, Dipipanone, Diprenorphine, Dronabinol, Met-enkephalin, Leu- Enkephalin, dynorphin A, dynorphin B, β-endorphin, eptazosazoline , eridorphin, ethoheptadine, 14-ethoxymethopone, ethylketone Cyclazocine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphyrin fencamfamine, fenethylline, fen Propolis, Fentanyl, a-Methylfentanyl, beta-Funaltrexamine, P -Hydroxy-3-methylfentanyl, heroin, hydrocodone, hydromorphone, Hydromorphodone, hydroxymethylmorphinan orphinan), hydroxypethidine, isomethadone, ketobemidone, xiotorphin, levo- a-Acetylmethadol, levoacetylmethadol, levacetylmethadol , Levomethadone, Levomethadyl acetate, Levallorphan, Levorphanol, Levophen Levophenacylmorphan, lofentanil, lofexidine, loperamine do, malbuphine, mazindol, melatonin, mefenorex, meperi meprobamate, meptazinol, metazocin, methadone, metopon, methyldihy Dromorphine, methyldihydromorphinone, methylmorphine, methyl Naltrexone, methylphenidate (and stereoisomers), methiprylon, metopon, Lufentanil (mirfentanil), modafmil, morphiceptin, morphinan, morphine Ne, Myrofin, Nabilone, Nalbuphine, Nalbuphine, Nalmefene, Nalorphine , naloxone, naloxone benzoylhydrazone, naltrexone, naltribene (nal triben), naltrindole, naltrindole isothiocyanate, narceine, na Natbuphine, Nicomorphine, Nor-binaltorphimine mine), norlevorphanol, normetadone, nalorphine, normorphine, norpi Panone, noscapine, ohmefentanyl, o-methylnaltrexone, Hen, onitazene, oxycodone, oxymorphone, papaveretam, papave Phosphorus, paregoric, pemoline, pemoline, pentazocine, pethidine, phendimetrazid phenmetrazine, phenadoxone, phene Phenomorphan, phenazocine, phenoperidine, pholcodeine ne), piminodine, pipradrol, piritramide, prenorphine, pro Profadol, Properidine, Prophetazine, Promedo Promedol, properidine, propiram, propoxyphene, propylhexedrine, Remifentanil, spiradoline, sufentanil, sufentanil tanyl), tapentadol, thebaine, tramadol, trefentanil, tilidine, bimi or their salts, or the opioids phenanthrene, morphinan, phenanthren, Benzomorphan, methadone, phenylpiperidine, propionamide 4-anilide piperidin 4-aryl piperidines, 4-heteroaryl piperidines, etc., and / or may comprise or consist of their salts and derivatives.
[0068] In one embodiment, the pharma- ceutical active ingredient is morphine, or a salt or derivative thereof. In another embodiment, the pharma- ceutical active ingredient may be apomorphine.
[0069] The first and / or second pharmacologic active ingredients are selected from the group consisting of hypophosphatemia, a condition commonly seen in infants with low birth weight. To treat metabolic bone disease in infants, for conditions related to osteopenia in premature infants. and / or a drug or substance capable of preventing The first and / or second pharma- ceutical active ingredient may be a potassium salt (e.g., phosphorus potassium acid phosphate), Sometimes, that happens.
[0070] The first and / or second pharma- ceutical active ingredients are intended to treat gastric and / or esophageal pathological conditions (e.g., vomiting, Drugs or substances that can treat and / or prevent symptoms such as vomiting, nausea, and reflux. The first and / or second pharmacologically active agent may comprise, consist essentially of, or consist of The ingredients include metoclopramide and / or its derivatives (e.g., metoclopramide hydrochloride), It may comprise, consist essentially of, or consist of.
[0071] The first and / or second pharmacologic active ingredients may be used to treat erectile dysfunction or other disorders that may affect motility. To treat and / or prevent progressive diseases of the nervous system (e.g., Parkinson's disease, etc.) The term may include, consist essentially of, or consist of, a drug or substance that can be administered.
[0072] The first and / or second pharma- ceutical active ingredients may be cannabis or a cannabis derivative (e.g. , cannabidiol and / or other cannabinoids), , or may consist of.
[0073] The first and / or second pharma- ceutical active ingredients comprise, consist essentially of, melatonin; Or it may consist of.
[0074] The formulations described herein are useful in humans, particularly where swallowing pills can be a problem, for example. Applications may include pediatric and / or geriatric care. Another area is the use of veterinary medicine. In veterinary medicine, where administering drugs can be difficult,
[0075] In some embodiments, the formulation is administered for a period of time (e.g., at least 1 hour). , or more hours [e.g., at least 2, 3, 4, 5, 6, 8 hours, or more] ]), may be provided to provide a sustained release of the active ingredient.
[0076] According to a second aspect of the invention, an orally dissolvable film comprising at least one layer comprising: Provided: a first resinate comprising a first ion exchange resin and a first pharma- ceutical active ingredient; a second resinate comprising a second ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
[0077] The first resinate and / or the second resinate are incorporated into the film (e.g., may be dispersed (e.g., non-uniformly) in at least one layer. (I).
[0078] The film (e.g., at least one layer) may include a matrix and / or binder. Preferably, the film (e.g., at least one layer) is a polymer The matrix may comprise (e.g., at least (e.g., at least the first resinate and the second resinate) to the remaining components of both layers. It may be possible for the glycerol to act as a binder (for the glycerol complex).
[0079] The first pharma- ceutical active ingredient and the second pharma- ceutical active ingredient may be the same, or may vary.
[0080] The first pharma- ceutical active ingredient and the second pharma- ceutical active ingredient may be the same. In such cases, the orally dissolvable film may include at least one layer comprising: be: a first resinate comprising a first ion exchange resin and a first amount of a pharma- ceutical active ingredient; a second resinate comprising a second ion exchange resin and a second amount of a pharma- ceutical active ingredient; and , Matrix and / or binder.
[0081] The first ion exchange resin and the second ion exchange resin can be the same; may vary.
[0082] In one embodiment, the first ion exchange resin and the second ion exchange resin are the same polymer. The composition may comprise, consist essentially of, or consist of a polymer resin.
[0083] The first and / or second resinates may be present in the film (e.g., at least one layer), may be in an amount of about 1-50 wt. %, for example, typically about 5-20 wt.
[0084] The ratio (weight ratio) of the first pharma- ceutical active ingredient to the first resin in the first resinate The ratio of the amounts of the components may be about 2:1 to 1:5, typically about 1:1 to 1:2 (eg, about 1:1.5).
[0085] The ratio (weight) of the second pharma- ceutical active ingredient to the second resin in the second resinate The ratio of the amounts of the components may be about 2:1 to 1:5, typically about 1:1 to 1:2 (eg, about 1:1.5).
[0086] The first ion exchange resin and / or the first resinate are in the form of particles (e.g., beads). may be provided in such a form.
[0087] The second ion exchange resin and / or the second resinate are in the form of particles (e.g., beads). may be provided in such a form.
[0088] The first ion exchange resin and / or the first resinate, and / or the second ion exchange resin Processing the ion exchange resin and / or the second resinate (e.g., coating, By applying a coating to the resinate particles, The initial release of the active ingredient from each resinate may vary (e.g., delayed). ) may occur.
[0089] The film (e.g., the at least one layer) may include one or more free or non-free It may further include an unloaded ion exchange resin.
[0090] The film (e.g., the at least one layer) may be free or unloaded. The first ion exchange resin may be included.
[0091] The film (e.g., the at least one layer) may be free or unloaded. The secondary ion exchange resin may be included.
[0092] The film (e.g., the at least one layer) may be free or unloaded. A third ion exchange resin may be loaded (i.e., the film is loaded with the first ion exchange resin). and a certain amount of free or non-free ion exchange resin different from the first ion exchange resin. (It may contain a third unloaded ion exchange resin).
[0093] The first ion exchange resin and the second ion exchange resin have different mesh sizes and and / or particles (e.g., beads) having a particle size. do.
[0094] The mesh size and / or particle size of each ion exchange resin or mixture of ion exchange resins the desired concentration of the active ingredient or drug, for example as described in relation to the first aspect of the invention. The release rate may be selected to provide a
[0095] In one embodiment, the first ion exchange resin has a first mesh size (e.g., 50 to 100 μm). 100, 100-200, or 200-400 mesh size range), and / or a first Particle size (e.g., in the range of 150-300 μm, 74-150 μm, or 37-74 μm) may comprise, or consist of, particles (e.g., beads), and said second The ion exchange resin may be a second mesh size (e.g., 50-100, 100-200, or 200 ~400 mesh size range), and / or a second particle size (e.g., 150 to 300 mesh size range). particles (e.g., beads) having a diameter in the range of 00 μm, 74-150 μm, or 37-74 μm; wherein the first mesh size or particle size and said second mesh size or particle size. is different.
[0096] In doing so, the film provides a first release rate of the first active ingredient. and release of the second active ingredient at a second, different release rate. The patient is provided with a predetermined amount of the first active ingredient delivered over a predetermined period of time, and at different predetermined times. This is particularly advantageous when a sustained release of the second active ingredient is required over a period of time. This also allows the patient to receive a given amount of a single active ingredient for a given period of time. Although such a release profile may be beneficial when needed, it is important to This may not be achievable by incorporating the drug into the ion exchange resin, whereas By incorporating drugs into ion exchange resins with beads of different sizes as above, It becomes possible to design an improved release profile for the drug.
[0097] The pharma- ceutical active ingredient contained in the first resinate may be associated with a first release rate. do.
[0098] The pharma- ceutical active ingredient contained in the second resinate may be associated with a second release rate. do.
[0099] The first resin may have a mesh size of about 50 to 100. The rate should be about 10-70%, e.g., about 20-60%, after 1 hour when measured at pH 1.2. There is.
[0100] The second resin may have a mesh size of about 200 to 400. The rate should be about 30-99%, e.g., about 50-95%, after 2 hours when measured at pH 1.2. There is.
[0101] The features described in relation to any other aspect of the invention may also be used in conjunction with a filter according to the second aspect of the invention. may equally apply to the do not have.
[0102] According to a third aspect of the present invention, there is provided a method for delivering one or more pharma- ceutical active ingredients to a subject. The method comprises orally administering an orally dissolvable film comprising at least one layer comprising: This includes: a first pharma- ceutical active ingredient; a resinate comprising an ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
[0103] The method may include dissolving the film in the oral cavity of the subject.
[0104] The methods can be performed in humans (especially pediatric and / or geriatric) or animals (e.g., canines and This may be done for companion animals, including cats.
[0105] The method may include the step of releasing the first pharma- ceutical active ingredient in a non-delayed manner. The term "non-delayed" refers to the time it takes for the film to dissolve or Upon disintegration, the first pharma- ceutical active ingredient is delivered (e.g., immediately delivered). As one skilled in the art will understand, this means
[0106] The features described in relation to any other aspect of the invention may also be applied to the method according to the third aspect of the invention. may be equally applicable and, for the sake of brevity, will not be repeated here.
[0107] According to a fourth aspect of the present invention, there is provided a method for delivering one or more pharma- ceutical active ingredients to a subject. The method comprises orally administering an orally dissolvable film comprising at least one layer comprising: This includes: a first resinate comprising a first ion exchange resin and a first pharma- ceutical active ingredient; a second resinate comprising a second ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
[0108] The first pharma- ceutical active ingredient and the second pharma- ceutical active ingredient may be the same, or may vary.
[0109] In a preferred embodiment, the first pharma- ceutical active ingredient and the second pharma-ceutical active ingredient are This may be the same.
[0110] The method includes dissolving or disintegrating the film in the oral cavity of the subject. There are times when this happens.
[0111] The method includes releasing a first active ingredient at a first release rate and releasing a second, different release rate. This may include releasing the second active ingredient at a rate that allows the patient to delivery of a predetermined amount of said first active ingredient over a predetermined period of time and a second active ingredient over a predetermined period of time. This can be particularly advantageous when a sustained release of the active ingredient is required. This is useful when a patient requires delivery of a specific amount of a single active ingredient over a specific period of time. Although such release profiles may occur, it is important to understand how drug release profiles can be achieved by incorporating a drug into a single ion exchange resin. This may not be achievable by incorporating two or more different sizes of beads. By incorporating a drug into an ion exchange resin having a specific viscosity, the release profile of the drug can be improved. This makes it possible to design an improved filter.
[0112] The features described in relation to any other aspect of the invention may also be applied to the method according to the fourth aspect of the invention. may be equally applicable and, for the sake of brevity, will not be repeated here.
[0113] According to a fifth aspect of the present invention, there is provided a method of treatment comprising administering to a subject a composition according to the first or second aspect of the present invention. The use of the oral dissolvable film according to the present invention is provided.
[0114] The uses include treating pain, migraine, headache, inflammation, metabolic bone disease, hypophosphatemia, nausea, vomiting, Gastroesophageal reflux disease, anxiety, breathing difficulties, sleep disorders, movement disorders (e.g., Parkinson's disease), etc. The present invention may include treating one or more diseases and / or conditions selected from the group consisting of:
[0115] The features described in relation to any other aspect of the invention may be used in accordance with the fifth aspect of the invention. may be equally applicable and, for the sake of brevity, will not be repeated here.
[0116] According to a sixth aspect of the present invention, there is provided a method for preparing an oral dissolvable film, said method comprising the steps of: The method comprises: a resinate comprising a first pharma- ceutical active ingredient; an ion exchange resin; and a second pharma- ceutical active ingredient. and, casting the formulation, which includes a binder, onto a support.
[0117] The formulation may further comprise a liquid medium.
[0118] Typically, the liquid medium comprises, or consists essentially of, an aqueous solvent (e.g., water). , may consist of, or may be.
[0119] The binder may, for example, comprise a polymer, as described in relation to the first aspect of the invention. It may consist essentially of, consist of, or be.
[0120] The method may include mixing the formulation prior to casting.
[0121] The method may include the preliminary step of preparing the resinate.
[0122] The resinate is prepared by dissolving the ion exchange resin and the second ion exchange resin in a liquid medium (e.g., water). The pharmaceutical preparation may be carried out by providing a pharma- ceutical active ingredient. This step may include: May include: - mixing the ion exchange resin and the second pharma- ceutical active agent in the liquid medium; - filtering the resinate; - rinsing the resinate; and / or - Allowing the resinate to dry.
[0123] The method may include removing the film from the support.
[0124] The features described in relation to any other aspect of the invention may be used in accordance with the sixth aspect of the invention. may be equally applicable and, for the sake of brevity, will not be repeated here.
[0125] According to a seventh aspect of the present invention, there is provided a method for preparing an oral dissolvable film, said method comprising: The method includes preparing a first resinate comprising a first ion exchange resin and a first pharma- ceutical active ingredient; a second resinate comprising an ion exchange resin and a second pharma- ceutical active ingredient; and a binder. and casting the agent onto the support.
[0126] The first and / or second resinate may be prepared as described in relation to the sixth aspect of the invention, Providing the ion exchange resin and each pharma- ceutical active ingredient in a liquid medium (e.g., water). It may be prepared by
[0127] The features described in relation to any other aspect of the invention may be used in accordance with the seventh aspect of the invention. may be equally applicable and, for the sake of brevity, will not be repeated here. [Brief description of the drawings]
[0128] The invention will now be described in detail with reference to the drawings in which: [Figure 1] Dissolution profile of 20 mg oral Thin-Film at pH 1.2 and 6.8 and comparison with commercial comparators (MST® Continus® Suspension and MST® Continus® Tablets (n=6)); [Diagram 2] Drug release profile at pH 6.8 after delayed casting; [Diagram 3] Serum concentrations of morphine sulfate after oral administration of controlled-release morphine sulfate oral syn·film to rats (n = 3, mean ± SD); [Figure 4]Drug release profile of thin films containing complexed diclofenac at pH 6.8; [Diagram 5] Drug release profile of uncomplexed potassium acid phosphate-containing thin films at pH 6.8; [Figure 6] Drug release profile of thin films containing 10 mg of uncomplexed metoclopramide hydrochloride; [Figure 7] Drug release profile of thin films containing 10 mg complexed metoclopramide hydrochloride; [Figure 8] Drug release profile of thin films containing complexed morphine sulfate and uncomplexed metoclopramide hydrochloride at pH = 6.8; [Figure 9] Drug release profile over time from 50-100 mesh metoclopramide resinate at pH 1.2 and 6.8; [Figure 10] Drug release profile over time from 50-100 mesh oxycodone resinate at pH 1.2 and 6.8; [Figure 11] Effect of mesh size on drug release of metoclopramide resonates at pH 1.2; [Figure 12] Drug release profiles from resinates of melatonin with Dowex 50-100 mesh and Amberlite IRP 69 resin with and without Eudragit RSPO compared to Circadin® tablets at pH 1.2; [Figure 13] Drug release profile of thin films containing resinate of melatonin with Amberlite IRP 69 and Eudragit RSPO compared to Circadin® tablets at pH 1.2 and pH 6.8. EXAMPLES
[0129] 1) Study of an oral thin film that releases morphine as a pharmacologic active ingredient Materials and Methods Preparation of drug resinates Strongly acidic cation exchange resin (Dowex) with 8% divinylbenzene crosslinking (登録商標) 50WX8,5 0-100 mesh [BDH Laboratory Supplies, Poole, UK; Lot K18954850 429]) in 100 ml of 4.0% (w / v) morphine sulfate (courtesy of Macfarlan Smith, Edinburgh, UK; Lot 13-003 96) in a distilled water solution at a ratio of morphine sulfate to resin (by weight) of 1:1.5. The mixture was then stirred magnetically (250 rpm) at room temperature for 24 hours in the dark. The drug-resin complex was then applied to a 47 mm 0.2 μm nylon membrane (Phenex (TM) , Phenomenex Inc., C The mixture was filtered through a filter (Hesshire, UK) and rinsed twice with distilled water. The filtrate was diluted and subjected to high performance liquid chromatography. The drug loading onto the exchange resin was assayed by HPLC (method described below). The degree of adhesion was indirectly determined. The drug-resinate was dried at 50° C. for 12 hours.
[0130] Formulation of oral thin films The solution contained 20 mg of morphine sulfate (prepared as above) loaded into an ion exchange resin complex. The oral thin film formulation was developed. The oral thin film was composed of the following: The solution was prepared from: 13.8% w / w drug resinate; As the film-forming polymer, 17.4% w / w pullulan (Cornelius, Hertfordshire, UK; Lot 1E0712); As a disintegrant, 2.3% w / w polyvinyl·polypyrrolidone (Sigma-Aldrich, Dorset, UK; Lot KI19107BI); As emulsifier, 1.6% w / w Sisterna SP70 [Sisterna, Roosendaal, The Netherlands; Batch No. 548Z22]; As a citrus flavoring agent, 1% w / w lemon 507940T (Firmenich, Meyrin, Switzerland; Batch No. 10 00710486); As a sweetener, 0.9% w / w sucralose (Tate & Lyle, London, UK; Lot XM1D009501) ; As a plasticizer, 0.2% w / w glycerol (Melford Labs Ltd, Ipswich, UK; Batch No. 19 256); and Distilled water.
[0131] All components were weighed using an analytical balance (A&D Instruments Ltd, Abingdon, Oxford, UK; Serial No. 142 The mixture was weighed out and homogenized in an Ultra-Turrax homogenizer (Janke & Kunkel, Staufen, Germany; Seri The polymer solution was mixed at 8000 rpm using a 300-mm diameter 1 ... Apply the film onto the paper with a micrometer-adjustable film applicator (She en; 1117 / 250mm) and cast at 1.4mm, then dried in a cabinet dryer (M The samples were dried at 40°C for 30 minutes in a vacuum oven (Ittitchell Dryers Ltd, Carlisle, UK). The oral thin film was then cut to the target weight.
[0132] Films were also prepared containing 5, 10 or 20 mg of morphine sulfate as shown in Table 1 below. : [Table 1]
[0133] High Performance Liquid Chromatography (HPLC) Methods Based on the study by Lee and Sabra (G. Lee, K. Sabra, Stability of morphine sulphate ate in ANAPA Plus ambulatory infusion device and PEGA infusion sets, Eur J Hosp Pharm-S P, 12 (2006) 76-80), ACE C18 column (diameter 4.6 mm × length 150 mm, solid particles diameter 5 μm) A reversed-phase HPLC method was developed using a 100-milliliter column packed with a stationary phase and fitted with a guard column of the same material. The flow rate was set at 1.5 mL / min and the wavelength for UV absorbance was set at 237 nm. An isochoric solution consisting of 1% (w / v) ammonium acetate in water and acetonitrile (90:10 v / v) was used. A lactic mobile phase was used for elution. 20 μL of sample was injected onto the column. Morphine sulfate dissolved in HPLC grade water (Macfarlan Smith, Edinburgh, UK; Lot 13-00396) was used to prepare standards, and all measurements were performed in triplicate.
[0134] Characterization Homogeneity of drug-resin dispersion and uniformity of content Ion exchange resin beads are not easily visible when viewed under a microscope or scanned or photographed with sufficient resolution. When photographed, the polymers are separated into groups to the extent that they can be individually identified and counted. It was observed that the color of the film was sufficiently different from the background of the film. To assess the uniformity of resinate distribution throughout the drug-resin complex, A single piece of oral thin-film material containing the body was scanned with an EPSON Stylus SX515W scanner. The image was scanned at 2400 dpi. A 5 mm square grid was overlaid on the image and the cells were The online random number generator (http: / / www.random Using the quantification algorithm (quantifier.izer.org / ), a set of 20 unique random cells was identified for analysis. For each square sample, separate drug-resin beads were imaged using ImageJ (Maryland, USA). The counts were done manually using image processing software. The beads on top were included in the count.
[0135] To evaluate batch-to-batch content uniformity, the inventors performed The requirements of the Pharmacopoeial monograph of the The morphine content of ten randomly selected dosage units must be within 5% of the stated content. (British Pharmacopoeia Commission, British Pharmacopoeia Volume III, For mulated Preparations: Specific Monographs, Prolonged-release Morphine Tablets, i n: British Pharmacopoeia 2014, The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA), London, England, 2014). Using compendial Type II dissolution equipment, each film was Disperse in 900 ml of 0.1N hydrochloric acid at 37°C and stir at 50 rpm using a paddle method for 48 hours. A portion of each solution was filtered through a 0.22 μm syringe filter and analyzed by HPLC with sulfuric acid. The morphine content was analyzed.
[0136] Microbial bioburden Bioburden analysis was performed on pullulan films according to ISO 11737-1. Soy agar was used for bacterial colony growth and incubated at 35±1°C for 3 days. Sabouraud dextrose agar was used for counting yeasts and fungi. and incubated at 22±1° C. for 5 days.
[0137] Tensile strength and disintegration properties of oral thin films The British Pharmacopoeia has set out general acceptance criteria for orally disintegrating films, which include The unit should be "the mechanical strength suitable to withstand handling without damage"
[0021] . A tensometer (Instron, High Wycombe, UK) was used to measure the strength of the plate. The elongation and load required to break a Lulan film was studied. A set of two 'jaws' Each film was clamped between the plates and the force to break (N) and the increase in length at break (mm) were recorded. To assess the disintegration of dosage forms, a novel methodology published by Preis et al.
[22] was applied. The method utilized an adaptation of an existing compendial device for dynamic assessment of tablet disintegration. Each oral thin film (n = 6) was attached to the upper edge with a small clip in a disintegration test apparatus (Co The device was suspended from the arm of a 100-millimeter-sized 10-cm 3-well plate (Pley Scientific, Nottingham, UK; Serial No. 21169). Add a second clip to the bottom edge, adding additional weight so that the total weight of the clip is 3 grams. Distilled water kept at 37°C was used as the disintegration medium. Set the water level so that half of the oral thin film is immersed when the film reaches its lowest point. A timer was started and its endpoint was the time when the oral thin film disintegrated and The weight was visually recorded as the point at which it fell.
[0138] thermal stability To evaluate the thermal stability of controlled release morphine sulfate oral thin films, The batch of film is heat sealed into an aluminum sheet pouch and then ink-sealed at 40°C ± 2°C. The samples were stored in an incubator for 6 months. At intervals (0, 3 and 6 months), samples were weighed and Ten randomly selected films were taken for analysis and drug content analysis at each time point. Each was weighed and dispersed in 900 mL of 0.1 M HCl at 37° C. for 24 hours (50% by paddle). The solution was filtered through a 0.22 μm syringe filter and subjected to HPLC. According to ICH guidelines, a change of more than 5% was The results were considered “significant”
[23] . A 2-sample t-test was performed and the results were analyzed using Minitab (登録商標) Statistics Groups were compared using FT16 (Ver. 16.2.4).
[0139] In vitro solubility Dissolution testing was performed using the paddle method as described in the British Pharmacopoeia. The dissolution media used were from the British Pharmaceutical Pharmacopoeia (British Pharmacopoeia Commission, British Pharmacopoeia 2014 Online. Append ix XII B. ANNEX: Recommendations on Dissolution Testing, in, London, England: T he Stationery Office on behalf of the Medicines and Healthcare products Regulato As described in the National Institute of Hygiene and Medical Research (MHRA), 2014, hydrochloric acid medium (pH 1.2) and phosphate buffer were used. Each dissolution vessel contained 900 mL of medium maintained at 37°C and rotated at 50 rpm. The paddle speed was 0.22. Drug concentration was determined by HPLC as described above. 0 min, 10 min, 20 min, 30 min, 1 h, 1.5 h, 2 h, and then 6 h through a 1 μm filter. Extractions were performed every hour up to 12 hours after MST. (登録商標) Continues (登録商標) 20 mg suspension (Napp P Harmaceuticals Ltd., Cambridge, UK; Batch No. 169935) was used as a comparison product. The same dissolution method was used to dissolve the MST (登録商標) Continues (登録商標) A sample of 10 mg tablet (Napp Pharmaceuticals Ltd, Cambridge, UK; Batch No. 176133) The release profiles were also obtained; samples were measured by UV spectrophotometry at 210 nm. .
[0140] Dissolution profiles were compared for statistical similarity using the f2 statistic. Microsoft Ex Using the cel add-in program (DDSolver), f2 similarity was calculated using the bootstrap method. The sex factor was calculated (Y. Zhang, M. Huo, J. Zhou, A. Zou, W. Li, C. Yao, S. Xie, DDSo lver: an add-in program for modeling and comparison of drug dissolution profiles , Aaps J, 12 (2010) 263-271). An f2 value above 50 indicates similarity between the dissolution profiles. did.
[0141] Delayed casting for industrial scale-up The production of oral thin films can be easily scaled up to industrial levels. However, the combination of technologies involved in the new controlled release formulations is a prerequisite. Prior to film preparation, the drug-resinate was added to a viscous stock solution for a sustained whether release of the active pharmaceutical ingredient may occur when the drug is suspended in To evaluate this, a mixture of 63.7% (w / w) distilled water, 19.1% (w / w) pullulan, 10.2% (w / w) drug-resinate (prepared as above), 2.5% (w / w) polyvinyl polypyrrolidone Don, 1.8% (w / w) Sisterna SP70, 1.1% (w / w) sucralose, 1.0% (w / w) lemon 507940 A viscous stock solution containing 0.5% (w / w) glycerol and 0.1% (w / w) of flavoring agent was homogenized. The solution was allowed to stand, and oral thin films were prepared from the mixture at 0, 24, and 48 hours. Before each casting, the mixture was rehomogenized by hand. For each time point, solubility was measured using HPLC and the method described above in phosphate buffer (BP). The samples were evaluated at pH 6.8.
[0142] In vivo single-dose pharmacokinetic study in rats Study design A pharmacokinetic study by Nakamura et al. (K. Nakamura, E. Nara, T. Fuse, Y. Akiyama, Ph.D.) armacokinetic and pharmacodynamic evaluations of novel oral morphine sustained r elasase granules, Biol Pharm Bull, 30 (2007) 1456-1460), a swelling layered polymer A systems-based, once-daily, controlled-release formulation of morphine hydrochloride was evaluated. A daily dose of 160 mg / kg morphine administered as controlled release granules to rats After 24 hours of dosing, plasma concentrations exceeded 250 ng / mL. In the study, a 40 mg / kg dose of morphine in water was administered to achieve a plasma concentration of 500 ng / mL. Based on this design, the inventors Healthy male Sprague Dawley mice weighing 342–371 g (mean (SD) weight 359.3 (9.8) g) were used. (登録商 標) A single-dose pharmacokinetic study was conducted in 12 rats. Flurane (IsoFlo (登録商標) (Abbott Laboratories Ltd, Berkshire, UK) under anesthesia, 50 mg A sustained release, orally dispersible, syn-physalis tablet containing morphine sulfate (135-146 mg / kg bw) The oral thin film was placed on the inside of the cheek using tweezers, and approximately 100 μL of Blood samples (400 μL) were taken at staggered intervals from the tail vein. were collected (under anesthesia) over a 24-hour period, with each rat contributing a total of four time points. , 3 samples at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours. Blood samples were placed in clean 1.5 ml PPE Eppendorf (登録商標) tube The samples were then collected at 9503 g for 10 min and allowed to solidify at 3-5°C in an upright position. Separate the serum by centrifugation for 1 h and transfer it to clean 2 ml Eppendorf flasks. (登録商標) Transfer to After terminal blood samples were taken, the rats were frozen at 80°C until analysis. The animals were euthanized using
[0143] Extraction of morphine sulfate from rat serum and HPLC-UV assay Regarding the detection of heroin, tramadol, and their metabolites in whole blood, Mahdy Based on the method published by T. Mahdy, TH El-Shihi, MM Emara, M. Giorgi, New HPL C method to detect individual opioids (heroin and tramadol) and their metabolite s in the blood of rats on combination treatment, J Chromatogr Sci, 50 (2012) 658 -665) developed a method for the extraction and subsequent quantification of morphine sulfate from rat serum. , clean 2 ml Eppendorf (登録商標) The experiment was carried out in a tube containing 20 μL of 5 μg / mL salt. Nalorphine acid (internal standard) solution (methanol solution) was added to 170 μl of morphine-containing 100 μL of rat serum and vortexed for 30 seconds. 85 μL of 0.2 M borate buffer (pH 9.0) was added and vortexed for 30 seconds. 1 mL of extraction solvent (methyl tert-butyl ether ( MTBE) was added and vortexed for 30 seconds. The samples were then washed by rotating the vials. The organic layer was separated by shaking at 40 rpm for 10 min and centrifuged at 9503 g for 10 min. ml Eppendorf (登録商標) The mixture was transferred to a tube and evaporated under nitrogen in a water bath at 40 °C. 2 × 1 mL further extractions were performed. After centrifugation, the organic layer was separated using the same Eppendorf (登録商標 ) The mixture was combined in a tube and evaporated to leave a single residue. The residue was diluted with 150 μL of mobile phase (1 % (w / v) ammonium acetate:acetonitrile [90:10] and 100 μL was applied to the HPLC column. I entered.
[0144] ACE C18 column (4.6 mm diameter × 150 mm length, packed with a stationary phase of 5 μm diameter) (Gas morphine sulfate and nalorphine were analyzed at 237 nm using a 100-mM column (fitted with a 100-mM column). The HPLC-UV detection was performed. The mobile phase was acetonitrile-ammonium acetate 1% (w / v) The analysis was performed in gradient mode at a flow rate of 2 mL / min. Table 2 shows the overall gradient method. The composition of the mobile phase is described below.
[0145] [Table 2]
[0146] To evaluate the recovery achieved by this extraction method, blank serum samples were The samples were mixed with known concentrations of morphine sulfate and internal standard, and the mixture was then subjected to 10 replicates. The morphine concentration was repeatedly measured and was in the range of 500-700 ng / mL. Validated according to guidelines (data presented briefly).
[0147] result Loading of morphine sulfate onto ion exchange resin The HPLC method for assaying morphine sulfate at 237 nm covers the concentration range of 1–30 μg / mL. The results showed good linearity (n = 5; R 2 = 0.9998), which is the solubility and content uniformity assay. The two morphine sulfate samples were then compared to determine the concentration of morphine sulfate in the 2.57 and Ponceau 4R (MST (登録商標) Continues (登録商標) In suspension When mixed with a colorant present in water that interferes with normal UV spectrophotometric measurements, No interfering peaks were observed. By analyzing the drug-resinate filtrate, It was found that 2.81% of the morphine sulfate did not form a complex with the ion exchange resin. Therefore, the resulting dried drug-resin complex had a morphine sulfate content of 39.519% (w / w). had the following characteristics:
[0148] Characterization Content uniformity A random sample of 10 oral thin films was prepared to determine whether each thin film was targeted. The content of morphine sulfate did not deviate by more than 5% from the 20 mg target content, and thus complies with the Pharmacopoeia Approval Standard. (Pharmacopoeial monograph). The mean (SD) morphine sulfate content was 20 The batch also contained individual dosage units of The mass uniformity was also compliant, as it did not deviate from the average mass by more than 7.5%. The mean (SD) oral thin-film mass was 110.12 (2.18) mg; range, 107.6 to 114.1 mg. I did.
[0149] Homogeneity of resinate dispersion The mean (SD) number of IER beads per 0.5 × 0.5 cm oral thin film sample was 60.6 (5 .65); range 51 to 70.
[0150] Microbial bioburden Evaluating the microbiological quality of the oral syn-films included the absence of fungal or yeast growth, and minimal There was no minimal bacterial growth (10-20 cfu). The pharmacopoeia's acceptance criteria are total aerobic microbial count (TAMC) and total microbial count (TCM). The total combined yeasts and molds (TYMC) count was 2000 and 200, respectively. It needs to be less than Ronnie forming units / gram.
[0151] Tensile strength and disintegration properties of oral thin films The mean (SD) load (Newtons) required to break the film was 25.6 (6.3); range 15.5 ~37.2. The mean (SD) increase in length at break, in millimeters, was 4.8 (1.1); The mean (SD) time to collapse was 6.15 (0.98) seconds; range 5.0 to 7.7. Ta.
[0152] thermal stability This batch showed no change in mass or morphine sulfate content of more than 5% upon storage for 6 months at 40°C. No t-test was observed, thus complying with the ICH requirements for thermal stability. The test showed that compared to time 0, mass (after 3 and 6 months, p-values were 0.308 and 0.860, respectively) was significantly higher than that of time 0. ) or drug content (p-values 0.168 and 0.681 after 3 and 6 months, respectively). It was not approved.
[0153] solubility Figure 1 shows the MST (登録商標) Continues (登録商標) Suspensions and MST (登録商標) Continues (登 録商標) The oral thin-film formulation at pH 1.2 and 6.8 compared to the tablet formulation The dissolution curve is shown.
[0154] Solubility Results After Delayed Casting The solubility profiles of the films cast after 0, 24 and 48 hours are shown in Figure 2. The results of the similarity study comparing the release profiles were 59.6 (0 vs 24 hours), 73.2 (0 vs 48 hours), and The f2 factors were 63.8 (24 vs 48 h) and 63.8 (24 vs 48 h). The tubing did not significantly affect drug release from the ion exchange resin. The availability of ions in the active stock medium must be sufficient to support exchange reactions for drug release. This is because ion exchange resin technology is not sufficient for oral syn-fil This reaffirms that the active ingredient is suitable for providing controlled release from pharmaceutical formulations, It is further proven.
[0155] In vivo single-dose pharmacokinetic study in rats Method Validation Extractions from spiked serum samples with morphine sulfate concentrations ranging from 500 to 700 ng / mL (n = 10) with a mean (SD) recovery of 97.5 (4.6)%. The HPLC-UV method was The peaks of both analytes appeared in the blank matrix. The detected impurities were sufficiently separated, and interference was avoided. The concentrations in spiked rat serum samples were 40 ng / mL and 150 ng / mL, respectively. Repeated extractions (n = 5) at the limit of extraction (148.4 ng / mL) yielded a mean recovery of morphine sulfate of 91.2 (1 2.1)%.
[0156] Single-dose pharmacokinetic results Rats were administered a single oral dose of a controlled-release morphine sulfate thin film. The serum morphine profile after administration is shown in Figure 3. The maximum (standard deviation) blood plasma concentration was 337.6 ng / mL. Concentration in the serum (C max ), but (T max ) obtained at 12 h. AUC calculated using the linear trapezoidal method 0-24h teeth, The mean plasma concentration was 6.18 μg h / mL.
[0157] Discussion 20 mg of morphine sulfate can be delivered over a 6-hour period (3-6 hours in vitro) A sustained release oral thin film (>80% release within 24 hours) is developed using ion exchange resin technology. The film was successfully formulated to be flexible, non-brittle, and had a sweet, citrus-like flavor. The oral synovial fluid had a flavor and aroma. The drug-resin complex was uniformly distributed throughout the film (relative standard deviation 9.3%). ), resulting in a dosage form that complies with pharmacopoeial standards with regard to mass and content uniformity. Oral thin films provide an alternative solid dosage platform for drug delivery. and because of its low available moisture content, formulations without the need for preservatives. This is a pediatric drug delivery system (in children, many antibiotics are It has become known that there are concerns about the toxicity of preservatives (e.g., benzoic acid esters). [J. Lass, K. Naelapaa, U. Shah, R. Kaar, H. Varendi, MA Turner, I. Lutsar, Hospitalised neonates in Estonia commonly receive potentially harmful excipients , BMC Pediatr, 12 (2012) 136]) is an attractive option for the inventors of The biological challenge results also demonstrated that oral ThinFilm was less effective in supporting microbial growth. Thin films have improved stability over liquid formulations, as well as other formulations such as tablets. Provides a discreet and convenient alternative to solid dosage forms. Unlike oral synthases, which often require measuring or reconstituting a small volume prior to administration, The film allows for accurate dosing and does not require additional water for administration. Oral thin films dissolve immediately on contact with saliva and are therefore easier to swallow than other solid dosage forms. The risk of choking for patients who cannot breathe is eliminated (R. Bala, P. Pawar, S. Khanna, S. Arora, Orally dissolving strips: A new approach to oral drug delivery y system, International journal of pharmaceutical investigation, 3 (2013) 67-76) They consist of minimal food or pharmaceutical grade excipients, making them This is inexpensive and can be easily scaled up.
[0158] MST (登録商標) Continues (登録商標) When compared to suspensions, our results show that Comparable, but not statistically identical (f2<50) dissolution profiles between the different formulations were obtained. Oral suspension products utilize the same ion exchange resin method for their release mechanism. However, we have found that our thin film preparations can effectively suppress the effects of the commercially available suspension. It has been found that a slower drug release profile is achieved compared to turbidity agents. This is probably due to the effect of surface area on the exchange rate. It contains the same ion exchange resin form but with a larger mesh size (i.e., smaller The particles have a smaller particle size, which results in more rapid diffusion out of the resin. The advantages of uniform particle size ion exchange resins, in: Dow Liquid Separations, The Dow Chemical Company, Ede Gemme, Belgium, 2006). MST (登録商標) Continues (登録商標) The tablets are controlled release In contrast to ion exchange techniques, ethyl cellulose was incorporated into the swollen matrix. These result in a significantly slower release profile in vitro. .MST (登録商標) Continues (登録商標) Data comparing the suspension with other formulations are available in the published literature. Although not available in the main database, pharmacokinetic data collected by Napp Pharmaceuticals Ltd. Then, MST (登録商標) Continues (登録商標) The suspension is equivalent to an immediate release morphine sulfate solution. and MST (登録商標) Continues (登録商標) It has been shown to produce an in vivo plasma profile equivalent to that of the tablet (Napp Pharm aceuticals Limited, MST Continus suspensions 20, 30, 60, 100 and 200 mg - Summar y of Product Characteristics (SPC), in: electronic Medicines Compendium (eMC), Our results show that the dissolution profile of our oral thin-film formulation is MST (登録商標) Continues (登録商標) Suspensions and MST (登録商標) Continues (登録商標) Tablets At pH 6.8, the release profile of our formulation was The IL was found to be statistically similar to the tablet preparation (observed f2 = 57.775). Therefore, the plasma profile of our formulation is comparable to that of human in vivo studies. It would be reasonable to assume that there is.
[0159] Our results from in vivo studies in rats complement the in vitro solubility profile. achieved by ion exchange resin technology, which is completed and delivered in an oral thin-film dosage design. The present study demonstrates controlled and sustained release of synthetic morphine sulfate at approximately 140 mg / kg in rats. After a single oral dose of 100 g, serum concentrations increased steadily over the first 6 hours and peaked at approximately 300 ng / mL. The mean serum morphine levels reached a plateau and reached maximum concentrations by 12 hours. also continued to rise.
[0160] Our results suggest that oral thin-films are a promising drug delivery technology for sustained release in oral administration. Ion exchange resins have been shown to be a suitable platform for predictable and a simple and effective method for controlling drug release with reproducible release profiles. These have proven to be an option and can be easily formulated into oral thin films. A wide variety of cation and anion exchange resins are commercially available, e.g. Some Meets Pharmacopoeial monograph standards (e.g., Amberlite TM IRP69[Po Sodium styrene sulfonate] (British Pharmacopoeia Commission, British Pharmacopoeia 2015 Online. General Notices. Sodium Polystyrene Sulphonate., in, London, England: The Stationery Office on behalf of the Medicines and Healthcar (MHRA, 2014). These will allow for a uniform supply of APIs that are suitable for a range of applications. This allows for the formulation of a range of release rate options. In addition to the resinate complex, it is also possible to formulate the composition with a certain amount of free drug. It is capable of delivering a rapid immediate release of its active ingredient followed by a continuous, sustained release. This makes it possible.
[0161] 2) Study of oral thin films that release other pharmacoactive ingredients Controlled release films containing diclofenac Diclofenac is used as an analgesic and as an anti-inflammatory drug.
[0162] Dowex, a strong base anion exchange resin with 8% divinylbenzene crosslinking (登録 商標) 1X8 (50-100 mesh) at a diclofenac to resin ratio of 1:1.5 by weight. Disperse 25 mM diclofenac sodium in distilled water and place on a magnetic stirrer. The drug-resin complex was then mixed with a 47 mm 0.2 μm nylon mesh for 24 hours. Ron's Phenex TM The mixture was filtered through a membrane and washed with distilled water. The filtrate was diluted and analyzed by UV spectrophotometer at 276 nm. The extent of drug loading was indirectly determined by assaying spectrophotometrically. The drug-resinate was dried at 50°C.
[0163] Ion exchange resin complex (Dowex (登録商標) 1X8, 50-100 mesh, prepared as above) A thin film formulation containing 12.5 mg of diclofenac sodium was prepared for oral administration. 15.9% (w / w) drug-resinate; 17.9% (w / w) pullulan (which is a film-forming polymer). 2.4% (w / w) polyvinyl polypyrrolidone as disintegrant; 0.2% (w / w) glycerol as a sweetener; 1.0% (w / w) sucralose as a sweetener; 1.0% (w / w) lemon flavoring to impart a citrus flavor and aroma to the film; 1.0% (w / w) lemon flavoring as an emulsifier Prepare a viscous stock mixture containing 0.7% (w / w) Sisterna SP70; and distilled water. All ingredients were weighed on an analytical balance and homogenized using an Ultra-Turrax homogenizer at 8000 rpm. The film was then applied to the micrometer-adjustable film applicator (Mic Using a rometer Adjustable Film Applicator, apply 100% Cast to a thickness of 0.4 mm and heat in a cabinet dryer at 40°C for 20 minutes. Allow to dry. Cut the oral thin film using a rotary blade and template.
[0164] A 50% entrapment efficiency was achieved at a drug loading of 41%, resulting in a drug loading of 21% (w / w). A resinate containing diclofenac sodium was obtained. The drug release from the combination oral thin films (n = 6) is shown in Figure 4.
[0165] The release of the drug was sustained over a similar period of time compared to morphine sulfate, and was approximately 5 hours later. It can be observed that the release is about 40%.
[0166] Immediate release films containing potassium acid phosphate Adequate phosphate intake is important for preventing metabolic bone disease in preterm infants. The purpose of this study was to determine whether hypophosphatemia, which is common in low birth weight infants and is associated with osteopenia in premature infants, is associated with hypophosphatemia. Oral syn-physeal supplementation is recommended for use as a source of phosphorus in the treatment and prevention of Incorporating potassium dihydrogen phosphate (KAP) into the formulation , was.
[0167] Three different strengths of oral thin films of KAP were prepared. was cast and the composition is set forth in Table 4 below.
[0168] [Table 3]
[0169] Using the official dissolution apparatus (Type II), dissolution rates were obtained over the physiological pH range (pH 1.2, 4.6, and 6.8). Therefore, potassium dihydrogen phosphate (potassium acid phosphate) was administered orally as a thin film bag. At all strengths, more than 95% of the drug was released within 15 minutes. Therefore, the formulation is considered to be "very rapidly dissolving" (World Health Organization , 2006).
[0170] Oral Thin Film batches meet pharmacopoeial standards of uniformity with respect to mass and drug content. It was found to be compatible.
[0171] The resulting drug release profile at pH 6.8 is shown in FIG.
[0172] From the release profile, it was found that for all three drug concentrations, the release profile was: The drug release was immediate, with 67-75% of the drug released after 5 minutes and 87-95% after 10 minutes. It can be seen that...
[0173] Immediate release films containing metoclopramide hydrochloride 8.6% (w / w) metoclopramide hydrochloride, 20.2% (w / w) water-soluble film-forming polymer Hydroxypropyl methylcellulose E5, sucralose 2.3% (w / w) as sweetener, 2.0% (w / w) spearmint flavor to give the film a mild minty flavor and aroma Taste additive, 0.9% (w / w) polyvinyl polypyrrolide to improve the disintegration properties of the film 0.8% (w / w) glycerol as a plasticizer and 0.7% (w / w) poly(ethylene glycol) The composition is composed of 0.3% (w / w) menthol as a flavoring agent, and distilled water. The components were weighed on an analytical balance and mixed with an Ultra-Turrax homogenizer. The film was then scanned at 8000 rpm using a micrometer adjustable film speed adjuster. Using the Micrometer Adjustable Film Applicator, apply the polymer coating. The samples were cast at 1.6 mm thickness on paper coated with cellulose acetate and then heated at 40°C in a cabinet dryer. Using a rotary blade and a 15 mm template, cut the oral thin film. was cut by hand.
[0174] Oral thin film batches are administered to the subjects, The lopramide content and average mass were within 10% of each other, so the product complies with the pharmacopoeia standards for uniformity. The mean (n = 10) drug content (SD) was 9.84 (0.51) mg, range 9.27 to 10.77 mg. The dose unit mass was 37.23 (1.91) mg, range 34.8 to 40.5 mg.
[0175] The resulting drug release profiles at three different pH values are shown in FIG.
[0176] From Figure 6, the release profile can be considered as "immediate" at all three pH values tested. It can be seen that the drug release is faster at lower pH (pH = 1.2 and pH = 4.6). It was observed that approximately 80% was released after 6 minutes and essentially complete release after 10 minutes. Drug release at .8 was somewhat slower, with approximately 53% released after 6 minutes and approximately 70% released after 10 minutes. It was done.
[0177] Controlled release films containing metoclopramide hydrochloride 10g of Dowex (登録商標) 50WX8 (50~100 mesh; 149~297 μm) (8% divinylbenzene 100 ml of 5% (w / v) metoclopramide hydrochloride (a strong acid cation exchange resin with cross-linking) was added to Disperse the mixture in a distilled water solution of BUFA (lot no. 13C12-B02) and place on a magnetic stirrer. The drug-resin complex was then mixed with a 47 mm 0.2 μm nanotube for 24 hours at 37° C. for 24 hours. Phenex TM , Phenomenex Inc., Cheshire, UK) and washed with distilled water. The filtrate was diluted and assayed by UV spectrophotometry at 275 nm to determine drug loading. The degree of drug loading was indirectly determined. and dried at 60°C.
[0178] Ion exchange resin complex (Dowex (登録商標) 50WX8, 50-100 mesh, prepared as above We developed an oral thin-film formulation containing 10 mg of metoclopramide hydrochloride loaded in a thin-film capsule. 14. 0% (w / w) drug-resinate; 18.3% (w / w) pullulan included as a film-forming polymer; 2.4% (w / w) polyvinyl polypyrrolidone as disintegrant; 0.1% (w / w) glucuronide as plasticizer glycerol; 1.1% (w / w) sucralose as sweetener; citrus flavor in oral thin film 1.0% (w / w) Lemon 507940T to impart flavor and aroma; 1.7% (w / w) Siste as an emulsifier A viscous stock mixture was prepared containing: RNA SP70; and distilled water. All components were The mixture was weighed on an analytical balance and mixed using an Ultra-Turrax homogenizer at 8000 rpm. Micrometer Adjustable Film Applicator Using a 300 mm thick plastic applicator, cast the film onto polymer-coated paper at a thickness of 1.4 mm. The plate was then dried in a cabinet dryer at 40°C for 20 minutes. The oral thin film was then cut to the target weight.
[0179] Oral thin film batches are administered to the subjects, The lopramide content and average mass were within 10%, so the product complied with the pharmacopoeial standards for uniformity. The mean (n = 10) drug content (SD) was 10.4 (0.3) mg, range 9.9 to 10.8 mg. The unit mass was 86.8 (4.2) mg, range 81.6 to 93.1 mg.
[0180] The results of the drug release profile at various pH values are shown in FIG.
[0181] From FIG. 7, at both tested pHs of 1.2 and 6.8, the release profile was “sustained.” It can be seen that this appears to be typical of a "stable" release formulation. Drug release was greater at pH 1 than at pH 6.8. At pH 6.8, the drug release was somewhat faster, at pH 6.8 the drug release was about 43% after 2 hours, at pH 1.2 the drug release was about 58% after 4 hours, was observed to be about 64% at pH 6.8 and about 81% at pH 1.2.
[0182] Syn-fil containing morphine sulfate conjugate and unconjugated metoclopramide hydrochloride M Dowex 50WX8 (50-100 mesh) was added to a 4% (w / v) aqueous solution of morphine sulfate. Disperse the resin at a ratio (by weight) of 1:1.5, and place in a dark place for 24 hours on a magnetic The resulting drug-resin complex was filtered and washed twice with deionized water. The filtrate (and wash) was diluted and assayed by UV spectrophotometry at 237 nm. Thus, the degree of drug loading was indirectly determined.
[0183] Drug-resinate containing 11.1% (w / w) morphine sulfate, 5.3% (w / w) metoclopramide hydrochloride , 21.9% (w / w) pullulan, 0.3% (w / w) glycerol, 0.9% (w / w) sucralose, 1.2% (w / w) Prepare orally dispersible thin films from a stock mixture containing Mon flavorings, and distilled water. The mixture was homogenized by hand and dispersed using a micrometer adjustable film applicator. The polymer-coated film was then applied using a Micrometer Adjustable Film Applicator. The film was cast onto paper at a thickness of 1.6 mm. The film was heated at 40° C. for 2 It was allowed to dry for 5 minutes and then cut to 30 x 15 mm using a rotary blade and cutting template.
[0184] A random sample (n = 10) of oral syn-film had a mean mean of 105.4 (2.14) mg, range 103.1–10 8.3 mg, 9.26 (0.17) mg, range 9.04 to 9.49 mg of morphine sulfate and 12.78 (0.26) mg, range 8.3 to 9.49 mg of morphine sulfate. Each contained between 12.50 and 13.13 mg of metoclopramide hydrochloride.
[0185] Figure 8 shows the oral thin film combination at pH 6.8 (n = 6). The release profile shows that metoclopramide hydrochloride is rapidly and immediately released within 10 to 20 minutes. More than 80% of the drug was released. Morphine sulfate was sustained-released over a 6-hour period. It was observed that 80% was released within the first 3-4 hours.
[0186] Thus, immediate release of one drug and a second drug provided in the resinate in the film can be achieved. The effectiveness of the films of the present invention for combining a drug delivery system with a sustained release drug delivery system has been demonstrated.
[0187] Controlled release films with oxycodone hydrochloride Preparation of drug resinates A strong acid cation-exchange resin (Dowex) with 8% divinylbenzene crosslinking (登録商標) 50 WX8, 50-100 mesh [Sigma Aldrich, UK]) was diluted with 100 ml of 4.0% (w / v) oxycodone hydrochloride (Ma The hydrochloric acid oxychloride was dissolved in distilled water (kindly provided by Cfarlan Smith, Edinburgh, UK). Disperse the mixture at a codon-to-resin ratio of 1:1.5 (by weight) and incubate at room temperature for 24 hours in the dark. The mixture was stirred with a magnetic stirrer (250 rpm). The drug-resin complex was then 47 mm 0.2 μm nylon membrane (Phenex TM , Phenomenex Inc, Cheshire, UK) The filtrate was diluted and assayed by UV spectrophotometry at 230 nm to determine The extent of drug loading onto the exchange resin was indirectly determined. The nate was dried at 50° C. for 12 hours.
[0188] Drug release was determined according to the British Pharmacopoeia 2014 Online. Appendix XII B. ANN EX: Recommendations on Dissolution Testing [Online]. London , England: The Stati onery Office on behalf of the Medicines and Healthcare products Regulatory Agency y (MHRA). Available: http: / / www.pharmacopoeia.co.uk / bp2014 / ixbin / bp.cgi?a=displa As described in [Accessed 06 / 10 / 2014]), the type Dissolution was evaluated using a 2.0 mm HCL dissolution apparatus. Dissolution was evaluated in two media: hydrochloric acid buffer (pH 1.2) and mixed. The evaluation was performed at 37°C ± 2°C using a synthetic phosphate buffer (pH 6.8). A fixed wavelength of 230 nm was used. UV measurements were taken at each time point. For each jar, the paddle was set at 50 rpm and 900 mL of Vehicle was used. Six replicates were performed for each pH buffer.
[0189] result Analysis of the drug-resinate showed that the resulting dry drug-resin complex had a 41.6% (w / w) The oxycodone hydrochloride content was shown to be
[0190] FIG. 10 shows the oxycodone resin at pH 1.2 and 6.8 for the 50-100 mesh resin. 6 shows the release profile of nate.
[0191] 40% was released from the ion exchange resin in 0.33 and 1.67 hours at pH 1.2 and 6.8, respectively. At 0.83 and 4 hours, 60% of the drug was released.
[0192] 3) Study of the effect of mesh size on drug release method 10 g of Dowex (登録商標) 50WX8 (50~100 mesh; 149~297 μm) (8% divinylbenzene Cross-linked strong acid cation exchange resin) was added to 100 ml of 5% (w / v) metoclopramide hydrochloride. The mixture was dispersed in a distilled water solution of 100 ml of 100% ethanol and stirred for 24 hours using a magnetic stirrer (250 rpm The drug-resin complex was then filtered and washed with distilled water. The filtrate was diluted and Drug loading was assayed by UV spectrophotometry using a validated method. The degree of oxidation was indirectly determined. The drug-resinate was dried in a cabinet dryer for 6 h. It was dried at 0°C.
[0193] For comparison, a second drug-resinate was prepared using a higher mesh size. Dowex (登録商標) 50WX8 (200-400 mesh; 37-74 μm) was mixed with methotrexate prepared in distilled water. Disperse metoclopramide in the clopramide solution at a ratio of 1:3 by weight of metoclopramide to resin. The mixture was stirred magnetically (250 rpm) for 24 hours.
[0194] Drug release was determined according to the British Pharmacopoeia 2014 Online. Appendix XII B. ANN EX: Recommendations on Dissolution Testing [Online]. London , England: The Stati onery Office on behalf of the Medicines and Healthcare products Regulatory Agency y (MHRA). Available: http: / / www.pharmacopoeia.co.uk / bp2014 / ixbin / bp.cgi?a=displa As described in [Accessed 06 / 10 / 2014]), the type Dissolution was evaluated using a 2.2 mm dissolution apparatus. Dissolution was evaluated in three media: hydrochloric acid buffer (pH 1.2), acetic acid, and 100% ethanol. The evaluation was performed at 37°C ± 2°C using a mixed phosphate buffer (pH 4.6) and a mixed phosphate buffer (pH 6.8). UV measurements were taken at each time point using a fixed wavelength of 275 nm. The rpm was set at 50 and 900 mL of media was used, with six replicates for each pH buffer.
[0195] result 50-100 mesh Analysis of the filtrate revealed that the metoclopramide recovery was 1.33%; therefore, The drug loading by the ion exchange resin was 98.67%, and the retention rate was 70%.
[0196] FIG. 9 shows the reactivity of metoclopramide at pH 1.2 and 6.8 for 50-100 mesh resin. 4 shows the release profile of ginate.
[0197] The resulting dry drug-resin complex had a metoclopramide content of 33.15% (w / w). From the ion exchange resin, 50% was released in 1.2 and 1.7 hours at pH 1.2 and 6.8, respectively. , 3.0 and 4.7 h, 80% of the drug was released.
[0198] 200-400 mesh Dowex (登録商標) When using 50WX8, 200~400 mesh, the same drug was found to have a 98.72% Drug loading was achieved. The resulting drug resinate contained 24.8% (w / w) metoclopramide. The metoclopramide release was evaluated at pH 1.2.
[0199] For 50-100 mesh resinate and 200-400 mesh resinate, pH 1.2 The results of the comparison of the release rates are shown in FIG.
[0200] As can be seen in Figure 11, the higher mesh size leads to a sustained but faster release. Release was observed after only 1 hour with 80% released.
[0201] In addition, as shown in Figure 11, the change in mesh size of the ion exchange resin significantly affected the release rate. At higher mesh sizes, metoclopramide is controlled to a greater extent. is released more quickly. Not wanting to be bound by theory, this is This is likely due to the influence of surface area effects on the exchange kinetics - the larger the mesh size, the The larger the particle size (i.e., the smaller the particle size), the greater the diffusion rate from within the resin. (The Dow Chemical Company; 2006; The advantages of uniform parts icle sized ion exchange resins [Online], Edegem, Belgium: The Dow Chemical Compa ny. Available: http: / / tinyurl.com / q5u4ac3 [Accessed 13 / 11 / 2014]). This means that It shows how the release kinetics can be easily manipulated according to clinical needs.
[0202] 4) Effects of Eudragit RSPO polymer on melatonin release Examination of the effects of various ion exchanges 1 g of Dowex (登録商標) 50WX8 (50-100 mesh; 149-297 μm [Sigma Aldrich, UK]) (8 100 ml of 0.18% (w / v) strong acid cation-exchange resin with divinylbenzene bridges Melatonin (Alfa Aesar, Lot: S16B032) was dispersed in a distilled water solution and then magnetically attached for 24 hours. The mixture was stirred at 250 rpm using a K-Stirrer. The drug-resin complex was then filtered and evaporated. The filtrate was diluted and analyzed by UV spectrophotometry using a validated method. The drug-resin was assayed to indirectly determine the degree of drug loading. The sheets were dried at 60° C. in a cabinet dryer.
[0203] The second drug-resinate was prepared by dispersing a strong acid cation in a melatonin solution prepared in distilled water. On-polystyrene sodium sulfonate-ion exchange resin Amberlite (登録商標) IRP 69 (50-150 μm [Dow Chemical Company]). Concentrate the ion exchange resin and melatonin solution by weight and place on a magnetic stirrer for 24 hours. The mixture was stirred at 250 rpm.
[0204] Amberlite prepared alone (登録商標) In addition to the IRP69 drug resinate, methacrylate Copolymer (Eudragit) (登録商標) RSPO [Rohm Pharma Polymers] The effect of adding a polymer to the resinate on melatonin release was investigated. The same method as described above for preparing Amberlite resinate was used. But 4g Eudragit (登録商標) RSPO was added at the same time. Ion exchange resin The Eudragit RSPO and melatonin solutions were incubated on a magnetic stirrer for 24 hours. Stirring (250 rpm) was performed and filtration was carried out as before.
[0205] Ion exchange resin complex (prepared as above, Eudragit (登録商標) Am with RSPO berlite (登録商標) Oral thin-film formulation containing melatonin loaded in IRP69 Developed by Eudragit (登録商標) 22.4% (w / w) drug-resinate containing RSPO; film-forming polymer 18.7% (w / w) pullulan as polymer; 1.1% (w / w) polyvinyl polyether as disintegrant liprrolidone; 0.1% (w / w) glycerol as a plasticizer; 0.5% (w / w) sugar as a sweetener Laurylose; 0.5% (w / w) to impart citrus flavor and aroma to the oral thin film 0.8% (w / w) Sisterna SP70 as emulsifier; and distilled water, A stock mixture was prepared. All components were weighed on an analytical balance and homogenized using an Ultra-Turrax homogenizer. The film was aligned at 8000 rpm using a micrometer adjustable film. Use the Micrometer Adjustable Film Applicator to apply the polymer coating. The mixture was cast onto paper with a thickness of 1.4 mm and dried in a cabinet dryer. The film was then dried at 40 °C for 20 min. Using a rotary blade, the film was targeted for oral administration. The weight was cut to the desired value.
[0206] Drug release was determined according to the British Pharmacopoeia 2014 Online. Appendix XII B. ANN EX: Recommendations on Dissolution Testing [Online]. London , England: The Stati onery Office on behalf of the Medicines and Healthcare products Regulatory Agency y (MHRA). Available: http: / / www.pharmacopoeia.co.uk / bp2014 / ixbin / bp.cgi?a=displa As described in [Accessed 06 / 10 / 2014]), the type Dissolution was evaluated using a 1.2 mL 1.2 dissolution apparatus. Dissolution was evaluated in two media: hydrochloric acid buffer (pH 1.2) and The evaluation was performed at 37°C ± 2°C using mixed phosphate buffer (pH 6.8). UV measurements were taken at each time point using a 900 mL centrifuge with the paddle set at 50 rpm for each jar. The media used were six replicates for each pH buffer. (登録商標) 2 mg tablets A 200 mg / kg / day 10 ... (Flynn Pharma Ltd., Stevenage, UK; Batch No. 60254A) was used as a comparison product. Dissolution was carried out by the same method.
[0207] result Dowex 50XW8 50-100 mesh Melatonin-resinate was observed to undergo a significant color change from orange to dark gray. This suggested an oxidation reaction between melatonin and Dowex 50XW8 ion exchange resin.
[0208] Figure 12 shows the Circadin (登録商標) Dowex 50XW8 50-100 mesh resin, parallel, compared to tablets and Amberlite IRP69 resin with and without Eudragit RSPO. The release profile of melatonin-resinate from the ion exchange resin at pH 1.2 is shown. After 30 min, 58.33% was released, and after 120 min, 89.8% was released.
[0209] Amberlite IRP 69 Compared to Dowex Melatonin Resinate, the melatonin solution was Amberlite (登録商標) I There was no significant color change when added to RP 69. At pH 1.2, melatonin release was evaluated. This was carried out and is shown in Figure 12.
[0210] As can be seen from FIG. 12, a much faster release of melatonin was observed, After just 10 minutes, 80% is released, which is the same as Amberlite (登録商標) IRP 69 Ion Exchange Resin This suggests that fat alone is not suitable for producing controlled release. This is compared to Dowex 50W8X, which is in bead form, and Amberlite (登録商標) IRP69 is a higher table This was expected because the powder is supplied with different mesh sizes. Using metoclopramide with Dowex resins in the range of That is what I did.
[0211] Amberlite IRP 69 and Eudragit RSPO As shown in Figure 12, Amberlite (登録商標) Combining IRP 69 with Eudragit RSPO In the case of the 120-minute release, 57.49% was released in 30 minutes and 81.4% was released in 120 minutes. x 50X8W ion exchange resin at a rate similar to that observed.
[0212] Polymethacrylates such as Eudragit RSPO, which are used for controlled release of drugs Amberlite IRP 69 resinate with Eudragit RSPO is well proven for use. It was expected that the addition of
[0213] Oral Thin Films of Amberlite IRP 69 and Eudragit RSPO Evaluation of melatonin release from oral thin-films was performed at pH 1.2 and pH 6.8 using Circadian in (登録商標) Figure 13 shows the results of the Circadin solubility test at pH 1.2 and pH 6.8 compared to the tablet. (登録商標) tablet Release profile of thin films containing Eudragit RSPO and melatonin resinate compared to Indicates a file.
[0214] As shown in Figure 13, at pH 1.2, the release rate of melatonin from the oral thin-film was Amberlite in combination with Eudragit RSPO alone (登録商標) Compared to IRP69 resinate, within 30 minutes This further decreased to 24% at 30 minutes and 73% within 120 minutes. This was 20.8% at 30 minutes and 62.8% at 120 minutes. Circadin showed a release rate of 3% (登録商標) The release profile of melatonin from the tablets Furthermore, at pH 6.8, the oral thin film showed 18% release at 30 min and 67% release at 100 min. Furthermore, Circadin tablets at pH 6.8 showed a release of 25% at 30 minutes and 63.7% at 120 minutes. .
Claims
1. 1. An orally dissolvable film comprising at least one layer comprising: a first pharma- ceutical active ingredient; a resinate comprising an ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
2. 10. A film according to any preceding claim, wherein the first pharma- ceutical active ingredient and / or Or the resinate is incorporated into at least one layer of the film.
3. 2. The film of any preceding claim, wherein the first pharma- ceutical active ingredient is about 0. It is provided in said at least one layer in an amount of .1 to 50% by weight.
4. 2. A film according to any preceding claim, wherein the resinate is present in an amount of about 1 to 50% by weight. is provided in said at least one layer in an amount of
5. 2. A film according to any preceding claim, wherein the second The weight ratio of the pharma- ceutical active ingredient to said resin is about 2:1 to 1:
5.
6. 2. A film according to any preceding claim, wherein the at least one layer is dispersed The first selected pharma- ceutical active ingredient is associated with a first release rate.
7. 7. The film of claim 6, wherein the first release rate is 5.0-10.0% when measured at pH 6.
8. After 1 minute, the fill rate is at least 30%, optionally at least 50%.
8. 7. The film of claim 6, wherein the first release rate is greater than or equal to 5% when measured at pH 1.
2. After 1 minute, it is at least 50%, optionally at least 60%.
9. A film according to any preceding claim, wherein said resinate comprises The two pharma- ceutical active ingredients are associated with a second release rate.
10. 10. The film of claim 9, wherein the second release rate is greater than or equal to 1 when measured at pH 6.
8. After a period of time, it is about 5-80%, optionally about 10-60%.
11. 10. The film of claim 9, wherein the second release rate is greater than or equal to 1 when measured at pH 1.
2. After a period of time, it is about 10-80%, optionally about 20-60%.
12. 2. A film according to any preceding claim, wherein the ion exchange resin is provided in the form of beads having a particle size and / or associated mesh size; The mesh size and / or particle size of the ion exchange resin or mixed ion exchange resin is It is selected to provide a desired release rate of the active ingredient or drug.
13. 13. The film of claim 12, wherein the resin is in the range of 50 to 100 mesh size. and / or has a particle size in the range of 150-300 μm.
14. 13. The film of claim 12, wherein the resin is in the range of 100 to 200 mesh size. and / or has a particle size in the range of 74 to 150 μm.
15. 13. The film of claim 12, wherein the resin is in the range of 200 to 400 mesh size. and / or has a particle size in the range of 37 to 74 μm.
16. A film according to any preceding claim, wherein the ion-exchange resin Resins and / or resinates resist degradation or dissolution in one or more areas of the digestive system. and a process selected to degrade or dissolve in one or more other areas of the digestive system. The active ingredient may be provided in the form of coated and / or encapsulated particles within the sealing material.
17. A film according to any of the preceding claims, wherein said at least one layer is It further comprises free or unloaded ion exchange resin.
18. 1. An orally dissolvable film comprising at least one layer comprising: a first resinate comprising a first ion exchange resin and a first pharma- ceutical active ingredient; a second resinate comprising a second ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
19. 20. The film of claim 1 or the film of claim 18, wherein the first pharmaceutical The primary pharma- ceutical active ingredient and the second pharma- ceutical active ingredient are the same.
20. 20. The film of claim 1 or the film of claim 18, wherein the first pharmaceutical The primary active ingredient and the second pharma- ceutical active ingredient are different.
21. A method for delivering one or more pharma- ceutical active ingredients to a subject, comprising at least one orally administering an orally dissolvable film comprising: a first pharma- ceutical active ingredient; a resinate comprising an ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
22. A method for delivering one or more pharma- ceutical active ingredients to a subject, comprising at least one orally administering an orally dissolvable film comprising: a first resinate comprising a first ion exchange resin and a first pharma- ceutical active ingredient; a second resinate comprising a second ion exchange resin and a second pharma- ceutical active ingredient; and Matrix and / or binder.
23. Pain, migraine, headache, inflammation, metabolic bone disease, hypophosphatemia, nausea, vomiting, gastroesophageal reflux disease , anxiety, difficulty breathing, sleep disorders, erectile dysfunction, and / or movement disorders (e.g., Parkinson's disease 21. A method for treating one or more conditions or diseases selected from the group consisting of the above-mentioned Use of the orally dissolvable film according to any one of claims 1 to 4.
24. A method for preparing an orally soluble film comprising: a first pharma- ceutical active ingredient; an ion exchange resin; and a resinate containing a second pharma- ceutical active ingredient; and a binder. and casting the resulting mixture into a solution.
25. A method of preparing an orally soluble film comprising: a first resinate containing a tertiary ingredient; a second resinate containing a second ion exchange resin and a second pharma- ceutical active ingredient. and a binder, casting a formulation onto the support. Methods including:
Citation Information
Patent Citations
Oral film containing enteric release opiate resinate
WO2013171146A1
